logo
Plus   Neg
Share
Email

Idera Pharma Announces Results From Phase 2 Clinical Trial Of IMO-2055

Idera Pharmaceuticals Inc. (IDRA) announced results of a randomized, controlled Phase 2 clinical trial of IMO-2055, the Company's investigational oncology product candidate targeting Toll-like Receptor 9 in combination with Erbitux (cetuximab) for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck or SCCHN in patients who previously progressed on chemotherapy.

The company noted that the study did not meet its primary endpoint of improved progression-free survival following treatment with IMO-2055 in combination with cetuximab compared to treatment with cetuximab alone. The median progression-free survival based on investigator assessments was 2.9 months in both arms; based on independent radiology review, it was 1.9 months in the cetuximab arm and 1.5 months in the combination arm.

The Phase 2 trial was designed and conducted by Merck KGaA of Darmstadt, Germany, under Idera's oncology collaboration with Merck KGaA that was terminated in November 2011.

As part of the termination, Idera regained from Merck KGaA all rights for developing TLR9 agonists for the treatment of cancer, including all rights to IMO-2055, and Merck KGaA agreed to conduct the Phase 2 trial through completion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca Cola said it has no plans to abandon single-use plastic bottles as its consumers still want to use them. Bea Perez, Coca-Cola's senior vice president for sustainability, told the BBC at the World Economic Forum in Davos that consumers like the single-use plastic bottles as they reseal and are lightweight. The Procter & Gamble Company (PG) reported that its second-quarter core earnings per share rose 14 percent year-on-year, due to lower non-core restructuring charges versus the prior year. Currency-neutral core earnings per share increased 15 percent. Organic sales were up five percent, for the quarter.... While reporting financial results for the fourth quarter on Thursday, JetBlue Airways Corp. (JBLU) provided its financial outlook for the first quarter and the full-year 2020. For the first quarter, the company expects earnings in a range of $0.10 to $0.20 per share. Capacity is expected to increase...
Follow RTT
>